Benmelstobart plus anlotinib, chemo, and radiation for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer that cannot be removed with surgery.
- You have not had any prior treatment for this lung cancer.
- You are between 18 and 75 years old.
- You are generally well enough to carry out daily activities (ECOG 0-1).
- Your organs (blood, kidneys, liver, heart) are functioning adequately.
- You have not previously taken drugs like anlotinib, apatinib, bevacizumab, or certain immunotherapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of an immunotherapy drug (benmelstobart) with chemotherapy, and sometimes another drug (anlotinib), for people with limited-stage small cell lung cancer. The goal is to see if this treatment helps shrink or control the cancer before surgery.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.